Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin

Autor: Hiroki Murayama, Naotsugu Oyama, Yohei Shinfuku, Tomoko Hayashi, Isao Tsumiyama, Tomoko Taniguchi
Rok vydání: 2019
Předmět:
Blood Glucose
Male
medicine.medical_specialty
endocrine system diseases
medicine.medical_treatment
Postmarketing surveillance
Type 2 diabetes
Cohort Studies
03 medical and health sciences
0302 clinical medicine
Japan
Internal medicine
Product Surveillance
Postmarketing
Medicine
Humans
Hypoglycemic Agents
Insulin
Pharmacology (medical)
Vildagliptin
In patient
Glycoside Hydrolase Inhibitors
Aged
Pharmacology
Glycated Hemoglobin
Dipeptidyl-Peptidase IV Inhibitors
business.industry
digestive
oral
and skin physiology
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
General Medicine
Middle Aged
medicine.disease
Metformin
Sulfonylurea Compounds
Diabetes Mellitus
Type 2
030220 oncology & carcinogenesis
Drug Therapy
Combination
Female
business
030217 neurology & neurosurgery
medicine.drug
Zdroj: Expert opinion on pharmacotherapy. 21(1)
ISSN: 1744-7666
Popis: Background: Vildagliptin is a dipeptidyl peptidase-4 inhibitor that reduces glycemia in patients with type 2 diabetes mellitus (T2DM). When approved in 2013, data on vildagliptin combined with >750...
Databáze: OpenAIRE
Externí odkaz: